ArticleDiagnostic pathology2014
Down-regulated miR-22 as predictive biomarkers for prognosis of epithelial ovarian cancer.
Article in Diagnostic pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Prognostic value of micro-RNA in ovarian cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Review
- The Role of microRNA in the Prognosis and Diagnosis of Ovarian Cancer.International journal of molecular sciences · 2025Review
- Review of the Different Outcomes Produced by Genetic Knock Out of the Long Non-coding microRNA-host-gene MIR22HGMicroRNA (Shariqah, United Arab Emirates) · 2025Review
- MicroRNAs as Potential Biomarkers of Environmental Exposure to Polycyclic Aromatic Hydrocarbons and Their Link with Inflammation and Lung Cancer.International journal of molecular sciences · 2023Review
- Metabolic pathways of potential miRNA biomarkers derived from liquid biopsy in epithelial ovarian cancer.Oncology letters · 2023Article
- miR-22-3p and miR-30e-5p Are Associated with Prognosis in Cervical Squamous Cell Carcinoma.International journal of molecular sciences · 2022Article
- Small Non-Coding-RNA in Gynecological Malignancies.Cancers · 2021Review
- MiR-22 regulated T cell differentiation and hepatocellular carcinoma growth by directly targeting Jarid2.American journal of cancer research · 2021Article
- Genetic Ablation of MiR-22 Fosters Diet-Induced Obesity and NAFLD Development.Journal of personalized medicine · 2020Article
- Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells.Journal of gynecologic oncology · 2020Article
- Serum miR-22 is a novel prognostic marker for acute myeloid leukemia.Journal of clinical laboratory analysis · 2020Article
- Evaluation of miR-22 and miR-21 as diagnostic biomarkers in patients with epithelial ovarian cancer.3 Biotech · 2020Article
- LncRNA MALAT-1 promotes growth and metastasis of epithelial ovarian cancer via sponging microrna-22.American journal of translational research · 2020Review
- MiR-22 suppresses the growth and metastasis of bladder cancer cells by targeting E2F3.International journal of clinical and experimental pathology · 2020Article
- Five serum microRNAs for detection and predicting of ovarian cancer.European journal of obstetrics & gynecology and reproductive biology: X · 2019Article
- Survival advantage and clinicopathological significance of microRNA-22 in cancers: a meta-analysis.Cancer management and research · 2019Article
- The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas.Scientific reports · 2018Article
- MiR-22 sustains NLRP3 expression and attenuates H. pylori-induced gastric carcinogenesis.Oncogene · 2018Article
- Effect of dietary components on miRNA and colorectal carcinogenesis.Cancer cell international · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies have demonstrated that microRNA-22 (miR-22) was deregulated in many types of cancers and was involved in various cellular processes related to carcinogenesis. However, the clinical significance and prognostic value of miR-22 in epithelial ovarian cancer (EOC) haven't been investigated.
methods109 pairs of fresh EOC tissue and matched adjacent normal tissue specimens were collected between May 2007 and March 2013. Real-time quantitative RT-PCR assay was performed to evaluate the expression levels of miR-22. The chi-square test was used to assess miR-22 expression with respect to clinicopathological parameters. The survival curves of the patients were determined using the Kaplan-Meier method and Cox regression, and the log-rank test was used for statistical evaluations.
resultsmiR-22 expression in EOC tissues was significantly lower than that in matched normal adjacent tissues (mean ± SD: 1.944 ± 1.026 vs. 4.981 ± 1.507, P<0.0001). Low miR-22 expression level was correlated with FIGO stage (P=0.006), tumor grade (P=0.03), and lymph node metastases (P=0.01). Kaplan-Meier analysis with the log-rank test indicated that low miR-22 expression had a significant impact on overall survival (44.4% vs. 64.5%; P=0.005) and progression-free survival (23.5% vs. 52.6%; P=0.004).
conclusionsOur data demonstrated that the expression of miR-22 was downregulated in EOC, and associated with overall survival as well as progression-free survival, suggesting that miR-22 could serve as an efficient prognostic factor for EOC patients. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_178.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.